Oncology
AbbVie to acquire ImmunoGen for approximately $10.1bn
December 1, 2023Sales and Marketing AbbVie, Oncology, acquisition
AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
November 29, 2023Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
Astellas Pharma to acquire Propella Therapeutics for $175m
November 20, 2023Business Services Astellas Pharma, Oncology, Properlla Therapeutics, acquisition
Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will …
FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment
November 17, 2023Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
FDA approves BMS’s Augtyro for lung cancer treatment
November 16, 2023Medical Communications FDA, Oncology, bristol myers squibb, lung cancer
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
November 9, 2023Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …
Evotec and Dewpoint Therapeutics enter strategic partnership
November 7, 2023Research and Development Dewpoint Therapeutics, Evotec, Oncology, R&D, oncology
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate …
Angiex’s IND application for AGX101 cleared by FDA
November 3, 2023Medical Communications AGX101, Angiex, FDA, Oncology
Angiex has announced that the US Food and Drug Administration has cleared its Investigational New Drug (IND) application for AGX101, …
NMPA approves CStone’s Cejemly for lymphoma treatment
October 31, 2023Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma
CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
October 30, 2023Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab
Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …
Latest content
FibroFind appoints Lee Borthwick as CEO
